RxDoctor Payments Data

Summer Noel, NP

Nurse Practitioner · Columbia, SCNPI 1609437417

Payments from drug & device makers

$2,380in general payments, 2019–2025

Across 101 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$497
  • Calliditas Therapeutics US Inc.$235
  • Inari Medical, Inc.$198
  • Amgen$187
  • Otsuka America Pharmaceutical, Inc.$153
  • Mallinckrodt Hospital Products Inc.$134
  • plus $977 from 17 others

What the payments were for

  • Food & beverage$2,377100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,380 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$89,787
Medicare patients
486
Services billed
2,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide44$83,523
FarxigaDapagliflozin Propanediol57$42,632
Sevelamer Carbonate39$9,235
Calcitriol83$1,202
Lidocaine11$915
Valsartan25$678
Lidocaine-PrilocaineLidocaine/Prilocaine14$458
Hydralazine Hcl44$436
Potassium Chloride36$393
Losartan Potassium49$281
Amlodipine Besylate52$184
Furosemide41$144
Atorvastatin Calcium14$95
Lisinopril22$73
Carvedilol27$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$67$83,52344 claims
AstraZenecaFarxiga$497$42,63257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →